Dermatology

Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals; For the treatment of plaque psoriasis , Approved March 2018

Family Medicine

Aimovig (erenumab-aooe) ; Amgen; For the preventive treatment of migraine in adults , Approved May 2018

Gastroenterology

Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018

Genetic Disease

Crysvita (burosumab-twza) ; Ultragenyx; For the treatment of X-linked hypophosphatemia, Approved April 2018

Hematology

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) ; Portola Pharmaceuticals; for the reversal of factor Xa inhibitors, Approved May 2018

Doptelet (avatrombopag) ; AkaRx; For the treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure, Approved May 2018

Lokelma (sodium zirconium cyclosilicate); AstraZeneca; For the treatment of hyperkalemia, Approved May 2018

Palynziq (pegvaliase-pqpz) ; BioMarin; For the treatment of phenylketonuria, Approved May 2018

Tavalisse (fostamatinib disodium hexahydrate); Rigel Pharmaceuticals; For the treatment of chronic immune thrombocytopenia, Approved April 2018

Immunology

Ilumya (tildrakizumab-asmn); Sun Pharmaceuticals; For the treatment of plaque psoriasis , Approved March 2018

Tavalisse (fostamatinib disodium hexahydrate); Rigel Pharmaceuticals; For the treatment of chronic immune thrombocytopenia, Approved April 2018

Infections and Infectious Diseases

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide); Gilead; For the treatment of HIV-1 infection in adults, Approved February 2018

Trogarzo (ibalizumab-uiyk); TaiMed Biologics; For the treatment of multidrug resistant HIV-1 infection, Approved March 2018

Musculoskeletal

Crysvita (burosumab-twza) ; Ultragenyx; For the treatment of X-linked hypophosphatemia, Approved April 2018

Nephrology

Jynarque (tolvaptan); Otsuka America; For the treatment of autosomal dominant polycystic kidney disease, Approved April 2018

Neurology

Aimovig (erenumab-aooe) ; Amgen; For the preventive treatment of migraine in adults , Approved May 2018

Oncology

Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved February 2018

Lutathera (lutetium Lu 177 dotatate); Advanced Accelerator Applications; For the treatment of gastroenteropancreatic neuroendocrine tumors, Approved January 2018

Pharmacology/Toxicology

Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo) ; Portola Pharmaceuticals; for the reversal of factor Xa inhibitors, Approved May 2018

Lucemyra (lofexidine); US Worldmeds; For the mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults, Approved May 2018

Pulmonary/Respiratory Diseases

Symdeko (tezacaftor/ivacaftor) ; Vertex; For the treatment of cystic fibrosis , Approved February 2018

Urology

Erleada (apalutamide); Janssen Oncology; For the treatment of prostate cancer, Approved February 2018